---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-312722"
form_type: "8-K"
ticker: null
cik: "0001501756"
company_name: "Adverum Biotechnologies, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:47:18.330603+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Adverum Biotech acquired by Eli Lilly; tender offer closes, merger completed

## Summary
- 64% of shares tendered; $3.56/share cash plus CVRs worth up to $8.91/share.
- Merger completed under DGCL Section 251(h); Adverum becomes wholly owned Lilly subsidiary.
- All incumbent directors and officers removed; new board and officers from Lilly appointed.
- Shares to be delisted from Nasdaq and registration terminated under SEC Form 25 and Form 15.
- Company charter and bylaws amended and restated effective at merger close.

## SEC filing metadata
- accession: 0001193125-25-312722
- form_type: 8-K
- cik: 0001501756
- company_name: Adverum Biotechnologies, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501756/000119312525312722/0001193125-25-312722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501756/000119312525312722/d96637d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-312722
- JSON: https://secwatch.observer/filing/0001193125-25-312722.json
- Plain text: https://secwatch.observer/filing/0001193125-25-312722.txt

## Source-grounded claims
- claim_id: 30a707967d3ff82c88ece1011b3b75bdf7a48a31
  claim: Adverum Biotechnologies, Inc.: Bylaws amended and restated in their entirety.
  evidence_excerpt: Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000119312525312722/0001193125-25-312722-index.htm
- claim_id: 786d7fb54ca520b7e8ae07682cfb3db65e287058
  claim: Adverum Biotechnologies, Inc.: Certificate of incorporation amended and restated in its entirety.
  evidence_excerpt: Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000119312525312722/0001193125-25-312722-index.htm
- claim_id: 08518d1e01bc5ea58a6f3f14680c28823c3b025f
  claim: Adverum Biotechnologies, Inc. underwent a change of control involving Eli Lilly and Company for $3.56 per Share in cash plus contingent value rights (closed 2025-12-09).
  evidence_excerpt: to purchase all of the issued and outstanding shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Company Common Stock”) in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest (the “Closing Amount”) and less any applicable tax withholding, plus (ii) one non-tradable contingent value right
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000119312525312722/0001193125-25-312722-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.